AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 101 min read$NUVL

Porter James Richard sold $2.7M of NUVL

Porter James Richard (President and CEO) sold 30,000 shares of Nuvalent, Inc. (NUVL) at an average of $88.53 ($87.97–$89.63, $2.66M total) across 3 trades on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Porter James Richard
Published Jun 10, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
medium confidence
Mentioned
$NUVL
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

The CEO’s open-market sale totaling ~$2.66M is newly disclosed, but the 10b5-1 designation suggests the trades were planned in advance.

02

Market read

Provides a fresh, primary-source datapoint on insider activity for NUVL, with limited standalone fundamental implication.

03

What to watch

Traders may overreact to insider sales; the key is whether there are concurrent disclosures (guidance, trial updates, financing) that are absent here.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-10 for a sale executed 2026-06-08

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Nuvalent, Inc.

Company-level read

Ticker impact

$NUVLNeutralMedium confidence
Context

Nuvalent CEO Porter James Richard sold $2.66M of NUVL shares via an open-market transaction disclosed on SEC Form 4 (10b5-1 plan).

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is primary-source and time-stamped, but it is a routine 10b5-1 sale rather than an unscheduled liquidation or new fundamental disclosure.

Market effects

Sector

No sector read-through; this is a single-company insider transaction with no stated operational/regulatory change.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    Nuvalent, Inc.

    Company whose shares were sold by its President and CEO under a 10b5-1 plan.

  • insider
    Porter James Richard

    President and CEO who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NUVL insider trading history →

Related articles

JUL 15
$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

investegate.co.uk4 min
JUN 10
$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

finance.yahoo.com7 min
JUN 9
$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

latimes.com6 min
JUN 9
$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

benzinga.com7 min
JUN 9
$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

rttnews.com6 min
JUN 9
$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.

benzinga.com4 min